Latest research suggest that the presence of a KRAS mutation may be inadequate for defining a clinically homogenous molecular group, as many KRAS mutant tumors lose reliance in K-Ras for survival. PKC powered apoptosis. Evaluation of this sub-group demonstrated elevated PKC reflection and an boost in the nuclear:cytoplasmic proportion of PKC. In addition, concentrating on… Continue reading Latest research suggest that the presence of a KRAS mutation may